Journal of Gastrointestinal Cancer

, Volume 48, Issue 3, pp 250–255 | Cite as

Is That Possible to Stop or Cease the NASH to Turn into HCC?

  • Ahmet UygunEmail author
Review Article

We do not exactly know this because the etiopathogenesis of non-alcoholic steatohepatitis (NASH) is not completely known. But this progression can slow down by taking certain measures.

Non-alcoholic fatty liver disease (NAFLD) is present in 20 to 40% of the general population in developed countries. NAFLD and NASH are the most common chronic liver diseases in the Western coutries [1].

NAFLD is more common in obese and diabetic subjects. Among all subjects with NAFLD, NASH can be seen within a range of 10–20%. The prevalence of NASH in the developed countries is approximately 2–6%. NASH accounts for more than 50% of cryptogenic cirrhosis [2].

NAFLD may progress to NASH with fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Probably 10% of NAFLD patients will progress to NASH over a period of 10 years. Ten percent of NASH patients will progress to liver cirrhosis over a period of 10 years. Ten percent of liver cirrhosis patients will progress to HCC within the same period [51]....


  1. 1.
    Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implication. Gastroenterology. 2012;142:711–25.CrossRefGoogle Scholar
  2. 2.
    Mc Cullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40:17–29.Google Scholar
  3. 3.
    Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma (HCC) in non alcoholic fatty liver disease. A multicenter prospective study. Hepatology 2015; 24; 28363.Google Scholar
  4. 4.
    Pisto P, Santaniemi M, Bloigu R, et al. Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study. BMJ Open. 2014;20:4967–73.Google Scholar
  5. 5.
    Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patient with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188–95.CrossRefGoogle Scholar
  6. 6.
    White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342–59.CrossRefGoogle Scholar
  7. 7.
    Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2014;60:110–7.CrossRefGoogle Scholar
  8. 8.
    Sorrentino P, D’Angelo S, Ferbo U, Micheli P, et al. Liver iron excess in patients with HCC developed on NASH. J Hepatol. 2009;50:351–7.CrossRefGoogle Scholar
  9. 9.
    Duan XF, Tang P, Li Q, Yu ZT. Obesity, adipokines and hepatocellular carcinoma. Int J Cancer. 2013;13:1776–83.CrossRefGoogle Scholar
  10. 10.
    Zambo V, Simon-Szabo L, Szelenyi P, Kereszturi et al. Lipotoxicity in the liver. World J. Hepatol 2013; 5: 550–557.CrossRefGoogle Scholar
  11. 11.
    Henao-Mejia J, Elinav E, Jin C, Hao L, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179–85.CrossRefGoogle Scholar
  12. 12.
    Oliveira CP, Stefano JT. Genetic polymorphisms and oxidative stress in NASH: a mini review. Clin res Hepatol Gastroenterol. 2015;39:35–40.CrossRefGoogle Scholar
  13. 13.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J med. 2003;348:1625–38.CrossRefGoogle Scholar
  14. 14.
    Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005;23:4742–54.CrossRefGoogle Scholar
  15. 15.
    Karagozian R, Derdak Z, Baffy G. Obesity–associated mechanisms of hepatocarcinogenesis. Metabolism. 2014;63:607–17.CrossRefGoogle Scholar
  16. 16.
    Schlesinger S, Aleksandrova K, Pischon T, et al. Abdominal obesity, weight gain during adulthood and risk of liver and biliary tract cancer in a European cohort. Int J Cancer. 2013;132:645–57.CrossRefGoogle Scholar
  17. 17.
    Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with NASH who develop HCC. Clin Gastroenterol Hepatol. 2011;9:428–33.CrossRefGoogle Scholar
  18. 18.
    Adami HO, Chow WO, Nyren O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88:1472–7.CrossRefGoogle Scholar
  19. 19.
    Nelson JE, Wilson L, Brunt EM, et al. Relationship between the pattern of hepatic iron deposition and histological severity in NAFLD. Hepatology. 2011;53:448–57.CrossRefGoogle Scholar
  20. 20.
    Hsiao PJ, Kuo KK, Shin SJ, Yang YH, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol. 2007;22:2118–23.CrossRefGoogle Scholar
  21. 21.
    Mc Glynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011;15:223–43.CrossRefGoogle Scholar
  22. 22.
    Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol. 2014;20:9217–28.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Speliotes EK, Yerges-Armstrong LM, et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011;7:1324–38.CrossRefGoogle Scholar
  24. 24.
    Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to NAFLD. Nat Genet. 2008;40:1461–5.CrossRefGoogle Scholar
  25. 25.
    Singal AG, Manjunath H, Yopp AC, et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109:325–34.CrossRefGoogle Scholar
  26. 26.
    Shen JH, Li YL, Li D, et al. The rs738409 (IL48M) variant of the PNPLA3 gene and cirrhosis: a meta-analysis. J Lipid res. 2014:487–95.Google Scholar
  27. 27.
    Zhu L, Baker SS, Gill C, et al. Characterization of the gut microbiome in NASH patients: a connection between endogenonus aicohol and NASH. Hepatology. 2013;57:601–9.CrossRefGoogle Scholar
  28. 28.
    Ren Z, Xu S, Jiang J, Zheng S. A novel diagnosis for early HCC based on intestinal microbiome. 21st Annual Meeting of the İnternational Liver Transplant Society, Chicago, 2015.Google Scholar
  29. 29.
    Dapito DH, Mencin A, Gwak GY, et al. Promotion of HCC by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–16.CrossRefGoogle Scholar
  30. 30.
    Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009;24:248–54.CrossRefGoogle Scholar
  31. 31.
    Singh S, Singh PP, Singh AG, et al. Anti-diabetic medications and the risk of HCC: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881–91.CrossRefGoogle Scholar
  32. 32.
    Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of HCC in NAFLD: a multicenter prospective study. Hepatology. 2015;47:36–9.Google Scholar
  33. 33.
    Reddy SK, Steel JL, Chen HW, et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology. 2012;55:1809–19.CrossRefGoogle Scholar
  34. 34.
    Leung C, Yeoh SW, Patrick D, et al. Characteristics of HCC in cirrhotic and non-cirrhotic NAFLD. World J Gastroenterol. 2015;21:1189–96.CrossRefGoogle Scholar
  35. 35.
    Torres DM, Harrison SA. NASH and non-cirrhotic HCC: fertile soil. Semin Liver dis. 2012;32:30–8.CrossRefGoogle Scholar
  36. 36.
    Schutte K, Schulz C, Poranzke J, et al. Characterization and prognosis of patients with HCC in the non-cirrhotic liver. BMC Gastroenterol. 2014;14:117–25.CrossRefGoogle Scholar
  37. 37.
    Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, Thung SN. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol. 2013;604860Google Scholar
  38. 38.
    Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of NASH: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134–40.CrossRefGoogle Scholar
  39. 39.
    Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver disease in patients with HCC in the United States. Hepatology. 2002;3:1349–54.CrossRefGoogle Scholar
  40. 40.
    Bertot LC, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17:774–88.CrossRefGoogle Scholar
  41. 41.
    Chettouh H, Lequoy M, Fartoux L, et al. Hyperinsulinemia and insulin signalling in the pathogenesis and the clinical course of HCC. Liver Int. 2015;35:2203–17.CrossRefGoogle Scholar
  42. 42.
    Zhao L. The gut microbiota and obesity: from correlation to causality. Nat rev Microbiol. 2013;11:639–47.CrossRefGoogle Scholar
  43. 43.
    Dongiovanni P, Romeo S, Valenti L. HCC in NAFL: role of environmental and genetic factors. World J Gastroenterol. 2014;20:12945–55.CrossRefGoogle Scholar
  44. 44.
    Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51:1820–32.CrossRefGoogle Scholar
  45. 45.
    Yun YH, Lim MK, Won YJ, et al. Dietary preference, physical activity and cancer risk in men: national health insurance corporation study. BMC Cancer. 2008;8:366.CrossRefGoogle Scholar
  46. 46.
    Montella M, Crispo A, Giudice A. HCC, diet, and metabolic factors. Hepat Mon. 2011;11:159–62.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Fedirko V, Duarte-Salles T, Bamia C, et al. Prediagnostic circulating vitamin D levels and risk of HCC in European populations: a nested case-control study. Hepatology. 2014;60:1222–30.CrossRefGoogle Scholar
  48. 48.
    Turati F, Trichopoulos D, Polesel J, et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol. 2014;60:606–11.CrossRefGoogle Scholar
  49. 49.
    Dongiovanni P, Petta S, Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015;63:705–12.CrossRefGoogle Scholar
  50. 50.
    Zhang H, Gao C, Fang L, Zhao HC, Yao SK. Metformin and reduced risk of HCC in diabetic patients: a meta-analysis. Scand J Gastroenterol. 2013;48:78–87.CrossRefGoogle Scholar
  51. 51.
    Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefGoogle Scholar
  52. 52.
    Pei Y, Zhang T, Renault V, Zhang X. An overview of HCC study by omics-based methods. Acta Biochim Biophys sin. 2009;41:1–15.CrossRefGoogle Scholar
  53. 53.
    Takaki Y, Saito Y, Takasugi A, et al. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from NASH. Cancer Sci. 2014;105:1254–60.CrossRefGoogle Scholar
  54. 54.
    Liu YL, Patman GL, Leathart JB, et al. Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of NAFLD associted HCC. J Hepatol. 2014;61:75–81.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.GATA Gastroenterology DepartmentAnkaraTurkey

Personalised recommendations